Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA)

Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine

(2015) K. Theys et al.   CLINICAL MICROBIOLOGY AND INFECTION

A Phase 1 Open Label Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Intramuscular TMC278 LA (the MWRI-01 Study)

(2014) Ian McGowan et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Impact of Drug Resistance-Associated Amino Acid Changes in HIV-1 Subtype C on Susceptibility to Newer Nonnucleoside Reverse Transcriptase Inhibitors

(2014) Adriaan E. Basson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis

(2014) A G A Jackson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography–tandem mass spectrometry

(2014) Laura J Else et al.   Bioanalysis

Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland

(2014) Miłosz Parczewski et al.   Journal of the International AIDS Society

Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies

(2013) M.R. Nelson et al.   HIV CLINICAL TRIALS

Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy

(2013) S. Lambert-Niclot et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses

(2013) S. Lambert-Niclot et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

(2012) Calvin J. Cohen et al.   AIDS

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

(2012) Lourdes Anta et al.   AIDS

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

(2009) H. Azijn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY